4

Estrogen receptor alpha and beta in health and disease

Min Jia, PhD, Research Assistant a, 2, Karin Dahlman-Wright, PhD, Professor a, b, 1, Jan-Åke Gustafsson, MD, PhD, Professor a, c, *

a Department of Biosciences and Nutrition, Karolinska Institutet, Novum, S-141 83 Huddinge, Sweden
b SciLifeLab, Department of Biosciences and Nutrition, Karolinska Institutet, S-171 21 Solna, Sweden
c Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, 3605 Cullen Blvd. Science and Engineering Research Center Bldg. 545, Houston, TX 77204-5056, United States

ARTICLE INFO

Article history:
Available online 26 April 2015

Keywords:
estrogen receptors
cancer
metabolic disease

Estrogen receptors alpha (ERα) and beta (ERβ) are transcription factors that are involved in the regulation of many complex physiological processes in humans. Abnormal ER signaling leads to development of a variety of diseases, such as cancer, metabolic and cardiovascular disease, neurodegeneration, inflammation, and osteoporosis. This review provides an overview and update on ERα and ERβ in health and disease with focus on their role in cancer and metabolic disease and in the context of recent years' success in providing genome wide data on ER function. Furthermore, potential clinical applications and challenges are also discussed. © 2015 Elsevier Ltd. All rights reserved.

Estrogens regulate various physiological processes such as cell growth, reproduction, development and differentiation. In premenopausal women, the ovaries are the primary site of estrogen synthesis producing the predominant estrogen 17β-estradiol (E2), which acts locally and systemically on target organs and cells. In postmenopausal women and in men, the source of E2 is local conversion of testosterone and androstenedione to E2 by the cytochrome P450 aromatase enzyme in extragonadal
sites, such as breast, brain and adipose tissue where it acts locally as a paracrine or intracrine factor. In addition to effects by E2 on normal cells and normal physiology, estrogens also play an important role in several pathological processes including cancer, metabolic and cardiovascular disease, neurodegeneration, inflammation, and osteoporosis. The cellular effects of estrogens are mediated by two estrogen receptors, ERα and ERβ.

**Estrogen receptors: expression, structure and isoforms**

The existence of an ER was demonstrated by Elwood Jensen in 1958 [1], and the corresponding gene was cloned in 1985. ERβ, was cloned from the rat prostate and ovary in 1996 [2]. ERα is mainly expressed in reproductive tissues (uterus, ovary), breast, kidney, bone, white adipose tissue and liver, while expression of ERβ is found in the ovary, central nervous system (CNS), cardiovascular system, lung, male reproductive organs, prostate, colon, kidney and the immune system. As members of the nuclear receptor protein family, ERs are found mainly in the nucleus, but also in the cytoplasm and mitochondria.

The ERα and ERβ genes are located on different chromosomes, 6q25.1 and 14q23.2, respectively. ERs are composed of three functional domains: the NH2-terminal domain (NTD), the DNA-binding domain (DBD), and the COOH-terminal ligand-binding domain (LBD) (Fig. 1). The NTD encompasses a ligand-independent activation function (AF1) domain involved in transcriptional activation of target genes, and with only 16% similarity between ERα and ERβ. The DBD is highly conserved between ERα and ERβ with 97% amino acid identity and mediates sequence-specific binding of ERs to DNA sequences in target genes denoted estrogen-responsive elements (EREs). In contrast, the LBDs of ERα and ERβ show a 59% overall amino acid sequence identity yet the ligand-binding pockets of the two subtypes show only minor differences in structure. Importantly, these small structural differences in the ligand binding pockets have allowed the development of subtype selective ligands. Propyl pyrazole triol (PPT) and 2, 3-bis (4-hydroxyphenyl)-propionitrile (DPN) are commonly used ERα and ERβ selective agonists, respectively. The LBD also contains a ligand-dependent activation domain (AF2).

Due to alternative splicing of ER-mRNAs, three ERα isoforms have been identified (Fig. 1). ERαΔ3 lacks exon 3, which encodes part of the DNA-binding domain [3]. ERα36 lacks both AF-1 and AF-2, and the last 138 amino acids (aa) are replaced with a unique 22 aa sequence [4]. ERα46 lacking aa 1-173

![Fig. 1](image)

Fig. 1. The structures of the ER isoforms. Different functional domains are highlighted: the NH2-terminal domain (NTD) in blue, DNA-binding domain (DBD) in orange, and the COOH-terminal or ligand-binding domain (LBD) in green. The NTD contains a ligand-independent activation function (AF1) region which is responsible for recruitment of co-regulatory proteins.
which includes AF-1, was first identified and characterized as a dominant negative inhibitor of ERα activity in osteoblasts [5]. For ERβ, at least four ERβ isoforms have been described, referred to as ERβcx/2, ERβ3, ERβ4 and ERβ5 [6] (Fig. 1). All ERβ variants have novel C-terminus, and are unable to bind estrogens and other investigated ligands.

**Genome-wide studies of ERs**

**ER cistromes**

Consistent with the fact that ERα and ERβ are highly homologous in their DNA-binding domains, identification of DNA binding regions showed substantial overlap in binding sites for the two ERs [7]. Both receptors interact with binding sites enriched in ERE motifs [8]. However, ERα and ERβ also display differences in bound DNA regions [9]. Additionally, the binding of one receptor affected the binding pattern of the other [10]. ER cistromes may correlate with human disease and response to treatment. For example, analysis of ERα DNA binding sites demonstrated that FOXA1 is a major determinant of estrogen-ER activity and endocrine response in breast cancer cells [11].

**ER transcriptomes**

Gene expression profiling of ERα showed up-regulation of for example cell growth related genes [12]. Enriched functional clusters of ERβ modulated genes included signal transduction pathways, and genes controlling cell cycle progression and apoptosis [13]. Analysis of ERα- and ERβ-mediated gene regulation in the T47D cell line with inducible expression of ERβ, revealed that ERβ had diverse effects on ERα regulated gene expression, enhancing or counteracting the effects of ERα [14]. ERβ inhibited approximately 70% of ERα regulated genes including genes involved in proliferation and metabolism [14]. These findings suggested that ERα and ERβ in breast cancer cells likely impact cell proliferation and the activities of diverse signaling pathways.

**ER interactomes**

ERs regulate transcription via recruitment of different transcriptional coregulators (CoRs), which play a central role in the activation (coactivators) or repression (corepressors) of genes. Less than 50% of these CoRs were common to both ERs, suggesting that differences in interactomes of the two ERs are likely to contribute to the distinct roles of the two receptor subtypes [15]. Comparative analyses of agonist (E2) versus antagonist tamoxifen (Tam), raloxifene (Ral) or ICI 182,780 (ICI)-bound ERα interacting proteins reveal significant differences among ER ligands that relate to their biological activity. In particular, the E2-dependent nuclear ERα interactome is different and more complex than those elicited by Tam, Ral, or ICI, which, in turn, are significantly divergent from each other [16].

**ERs and cancer**

**ERs and breast cancer**

**ERα and breast cancer**

ERα is expressed in not more than 10% of normal breast epithelium but approximately 50–80% of breast tumors [17]. It is found in both ductal and lobular epithelial and stromal cells.

The role of ERα in mammary gland development has been demonstrated in ERα knockout (ERαKO) mice [18]. ERα promotes tumorigenesis and progression of breast cancer. Anti-hormonal therapy is commonly used in breast cancer patients with ERα expression, including the selective estrogen receptor modulators (SERMs) tamoxifen, raloxifene and toremifene, the selective estrogen receptor degrador fulvestrant, and the aromatase inhibitors anastrozole, letrozole and exemestane. Tamoxifen is the most effective and widely used antiestrogen therapy for breast cancer. However, only 70% of ERα positive breast cancers respond to tamoxifen treatment and 30–40% of patients receiving therapy relapse and become resistant to this therapy [19]. Additionally, tamoxifen, serving as an estrogen
antagonist in the breast, mimics estrogen effects acting as an estrogen agonist in other tissues, such as bone, endometrium and the cardiovascular system, thus having potentially severe side effects in these tissues. Another SERM, raloxifene, is reported to have less profound side effects compared to tamoxifen, particularly with decreased risk of endometrial cancer and thrombosis.

The ratio of ERα3 to wild type ERα is substantially reduced in all breast cancer cell lines and in breast cancers, suggesting that loss of the ERα3 isoform is associated with an early event in carcinogenesis. Molecular studies suggest that ERα3 functions as a dominant negative regulator of ERα. ERα36 has been shown to correlate with carcinogenesis, aggressiveness, and therapeutic response of breast cancer. Binding to the same target DNA sequence as wild type ERα does, ERα36 is expected to function as a powerful competitor of ERα. However, ERα36 mainly locates to the plasma membrane and to the cytoplasm where it activates rapid membrane-initiated non-genomic pathways. In recent years, studies have focused on the association between ERα36 and tamoxifen resistance [20]. Additionally, ERα36 is highly expressed in ERα-negative breast cancer. ERα46 acts as a negative regulator of breast cancer. Its overexpression inhibited MCF-7 breast cancer cell proliferation and inhibited E2-induction of the cyclin D1 promoter [21] and ERα regulation of pS2 gene [22]. ERα46 levels were reduced in tamoxifen resistant breast cancer cells and ERα46 re-expression inhibited cell proliferation [23].

ERβ and breast cancer

ERβ knockout (ERβKO) mice undergo an overall normal mammary gland development. However, subtle effects associated with decreased differentiation and increased proliferation in the alveoli of lactating mammary glands are sometimes observed in these mice [24]. Approximately 80% of normal breast epithelial cells express ERβ. Its expression is decreasing and even lost during breast cancer progression, which is associated with promoter hypermethylation [25]. In vitro studies showed that re-expression of ERβ in breast cancer cell lines inhibited cell proliferation, promoted apoptosis and enhanced the efficacy of chemotherapeutic agents [26]. Clinical evidence also revealed that loss of ERβ expression is associated with a poor prognosis [27] and resistance to endocrine therapy [28]. ERβ inhibits breast cancer cell proliferation through repressing activation of MAPK and PI3K signaling pathways [29]. Regulation of genes controlling cell cycle progression and apoptosis, may also contribute to the suppression of cell proliferation [13]. However, a few studies claim that ERβ expression is associated with enhanced cell proliferation, and is a poor prognostic factor in breast cancer [30,31]. Other studies claimed that ERβ expression was not correlated with clinical outcome in breast cancers in postmenopausal patients [32].

The expression and role of ERβ2 in breast cancer remain unclear [33]. Some studies showed that ERβ2 expression levels are lower in cancer compared with the corresponding normal tissues, indicating a protective role in breast cancer. Consistently, studies showed that ERβ2 is a good prognostic indicator in breast cancer. A possible mechanism may be repression of ERα activity by induction of proteasome-dependent degradation [34]. Other studies report opposite effects, and claim that ERβ2 expression is indicative of cellular proliferation [35]. Some studies showed that ERβ2 predicted the response to endocrine therapy [36] while other studies did not reproduce such effects [37].

ERβ5 exhibited protective role in breast cancer patients. Studies of clinical samples showed a positive association of ERβ5 expression with a longer relapse-free survival (RFS) [38] and a significant correlation of its nuclear expression with overall survival (OS) [36]. Recently ERβ5 has also been found to confer sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis [39].

ERs and ovarian cancer

In reproductive age women, ERα is present in the ovarian stroma and thecal cells, ovarian surface epithelium and in corpus luteum. For postmenopausal women, ERα is found in the ovarian surface epithelium, in epithelial inclusion cysts and in the stroma. In contrast, ERβ is localized predominantly in the granulosa cells [40].

Most ovarian cancer patients express ERα and/or ERβ. The expression levels of ERα are closely associated with estrogen-dependent growth, invasion and response to endocrine therapy in ovarian cancer. ERα is a direct target of the tumor suppressor microRNA (miR)-206, which is down-regulated in ERα-positive ovarian cancer cell lines and tissues. Introduction of miR-206 mimics inhibits cell
proliferation and invasion of ovarian cancer cells [41]. Recent studies show that effects of ER\(\alpha\) in promoting ovarian cancer progression could be mediated by long non-coding RNAs, such as TC0100223, TC0101686 and TC0101441. TC0101441 was reported as an independent prognostic factor for overall survival [42]. Expression of ER\(\alpha\) and its promoting role in ovarian cancer suggested that endocrine therapy could be an attractive treatment option. However, anti-estrogen treatment is not commonly used in ovarian cancer due to modest response rate.

ER\(\beta\) levels and/or the ER\(\beta\)/ER\(\alpha\) ratio decreases along with ovarian carcinogenesis, indicating that loss of ER\(\beta\) expression may be involved in carcinogenesis. Treatment with the ER\(\beta\) agonist DPN or re-introduction of ER\(\beta\) significantly suppressed cell growth in both ovarian cell lines and xenografts [43–45]. The inhibitory effects of ER\(\beta\) were mediated via down-regulating total retinoblastoma (Rb), phosphorylated Rb, phospho- RAC-alpha serine/threonine-protein kinase (AKT) as well as cyclins D1 and A2, and up-regulating cyclin-dependent kinase inhibitor p21 (WAF1). In addition, ER\(\beta\) had a direct effect on ER\(\alpha\) by strongly inhibiting its expression and activity.

Interestingly, some studies revealed that normal ovarian epithelium exhibited almost exclusively strong nuclear staining of ER\(\beta\), while ovarian cancer tissue mostly showed cytoplasmic immunopositivity, and cytoplasmic ER\(\beta\) expression was shown to be an independent unfavorable prognostic factor for disease free survival [46]. Furthermore, cytoplasmic ER\(\beta2\) expression was also reported to be associated with reduced 5-year survival and chemoresistance [47]. These novel findings suggest that ER\(\beta\) and its isoforms may have different roles and be associated with distinct prognosis depending on their cellular localization.

**ERs and prostate cancer**

In addition to androgens, estrogens may also affect prostatic growth and development, as shown in ER\(\alpha\)KO mice which display altered branching morphogenesis [48]. In the adult mouse prostate there is very little ER\(\alpha\) expression and most of it is in the stromal compartment. ER\(\beta\) is expressed at high levels in prostatic epithelium in adult mice and humans. Knockout of ER\(\beta\) causes hyperplasia of the ventral prostate as well as increased cellular Ki67-positivity [49].

In humans, the expression of ER\(\alpha\) is gradually increased from prostate intraepithelial neoplasia, invasive cancers to metastatic lesions at both mRNA and protein level. Studies of ER\(\alpha\)KO mice revealed that ER\(\alpha\) is an important determinant of prostate carcinogenesis [50]. In comparison to ER\(\alpha\), ER\(\beta\) is gradually lost during prostate carcinogenesis due to DNA promoter methylation [51]. Combined treatment of prostate cancer cell lines in vitro with DNA methyltransferase and histone deacetylase inhibitors have been shown to effectively restore ER\(\beta\) expression, with reduced proliferation and increased apoptosis [52]. Therefore, ER\(\beta\) has emerged as a promising new target for prostate cancer treatment.

Many trials have shown strong effects of antiestrogen for the treatment of prostate cancer. Studies showed a significant decrease in early prostate cancer progression when men were given toremifene [53]. The SERM raloxifene caused apoptosis in androgen-independent ER\(\alpha\) (−) ER\(\beta\) (+) PC3 cells [54]. Additionally, raloxifene was found to inhibit growth of prostate cancer lung metastasis [55].

Although ER\(\beta\) is silenced or reduced in the majority of prostate adenocarcinomas, some studies showed that patients with ER\(\beta\)-positive cancers have a significantly decreased relapse-free survival [56].

**ERs and colon cancer**

Clinical and animal studies show that hormone replacement therapy (HRT) reduces the risk of colon tumor formation in females. Additionally, men are more likely to develop colorectal cancer compared with women of similar age. These findings indicate that estrogen may lower the risk for colorectal cancer. ER\(\alpha\) mRNA levels are much lower than ER\(\beta\) levels and are similar between normal mucosa and tumor samples. ER\(\beta\) is the predominant ER in the colonic epithelium and the ER\(\beta\) level is lower in colon cancer compared to normal tissue. The decreased levels of ER\(\beta\) in colorectal cancer occurred in parallel to loss of differentiation and advanced Dukes staging. The protective role of ER\(\beta\) in colon cancer progression has been confirmed in in vivo studies in mice that spontaneously develop intestinal
adenomas (ApcMin/+) in which deletion of ERβ lead to an increase in the size and number of adenomas [57] and where treatment with an ERβ-selective agonist had the opposite effect [58]. Genome-wide studies of colorectal cancer cell lines re-expressing ERβ showed that besides apoptosis, cell differentiation, and regulation of the cell cycle are the most affected functional consequences. ERβ re-expression also down-regulates IL-6 and its downstream networks, which indicates that ERβ mediated antiinflammatory mechanisms are involved in colon carcinogenesis [59]. In the same model, the oncogenic miR-17-92 and miR-200a/b were found to be strongly down-regulated upon re-expression of ERβ [60].

**ERs and metabolic disease**

Estrogens have been clearly shown to regulate glucose and lipid metabolism using either models of estrogen-/ER-depletion or estrogen application/replacement. Estrogen deficiency promotes metabolic dysfunction predisposing to obesity, the metabolic syndrome, and type 2 diabetes (T2D). In rodents, it has been demonstrated that aromatase, the key enzyme of estrogen production, knockout (ArKO) mice display insulin resistance (IR), impaired glucose tolerance (IGT), and increased abdominal fat, which are reversible by E2 treatment [61]. Ovariectomy (OVX), resulting in low estrogen levels, leads to increased body weight, basal blood glucose and IGT which are reversible by re-introduction of estrogen [62]. Studies of ob/ob and high fat diet (HFD) fed mice, models of obesity and T2D, showed that estrogen treatment lowers body weight, improves glucose tolerance and insulin sensitivity in both mouse models [63,64]. In humans, the prevalence of early insulin resistance and glucose intolerance is higher in men than in women [65]. Postmenopausal women with estrogen deficiency were shown to have an accelerated development of visceral obesity, IR and T2D [62]. Several clinical trials involving postmenopausal women on hormone replacement therapy (HRT) demonstrated a reduced incidence of T2D, lower glucose plasma levels, and improved systemic insulin sensitivity [62,66]. It has been well documented that estrogens regulate energy homeostasis via both central and peripheral tissues (Fig. 2).

**Central regulation of energy balance by estrogens**

The hypothalamus is an essential area in the CNS that controls food intake, energy expenditure, and body weight homeostasis. Lesion of specific hypothalamic nuclei led to disorders of central energy homeostasis, such as the ventromedial hypothalamus (VMH) or the lateral hypothalamic area. ERα is abundantly expressed in the brain in the ventrolateral portion of the VMN, the arcuate nucleus (ARC), the medial preoptic area, and the paraventricular nuclei. ERβ is found in the same hypothalamic nuclei, but its expression is significantly lower relative to ERα. ERα seems to be the major regulator of central energy homeostasis. ERα silencing in the VMN resulted in an increase of food consumption as well as reduced energy expenditure caused by diminished physical activity and impaired thermogenic responses to feeding [67]. OVX-rats and -mice treated with E2 and PPT exhibited a strong ERα-dependent inhibitory effect on eating behavior [68]. On the contrary, ERβ deletion did not promote food intake and/or obesity [69].

**Peripheral regulation of energy balance by estrogens**

**Estrogens regulate lipid metabolism in adipose tissue**

Adipose tissue plays a major role in the regulation of lipid and glucose homeostasis and insulin sensitivity including via estrogen signaling. Estrogens affect adipose tissue by induction of lipolysis (e.g. due to activation of hormone-sensitive lipase, HSL) and reduction of lipogenesis, mostly by decreasing activity of lipoprotein lipase (LPL). Estrogens also increase the expression of insulin receptors in adipocytes, which enhances insulin sensitivity.

Both ER isoforms are expressed in adipose tissue. Both female and male ERαKO mice exhibit increased adipose tissue mass, IR and IGT, as well as adipocyte hyperplasia and hypertrophy [70,71] in white adipocyte tissue [72]. The role of ERβ in glucose and lipid metabolism in adipocytes is less clear. ERβKO in male mice resulted in animals with a similar body weight and fat distribution, as well as lipid and insulin levels, when compared to control. However, ERβKO female mice under HFD showed a
higher weight gain than their wild type littermates. These effects were closely associated with a strong activation of peroxisome proliferator-activated receptor gamma (PPARγ), a key adipogenic and lipogenic factor [73]. Recent studies of female OVX Wistar rats under HFD showed that ERβ-selective agonists significantly decreased lipogenic (sterol regulatory element-binding protein-1C (SREBP-1c)), fatty acid synthase (FAS) and adipogenic genes (LPL, PPARγ) in adipose tissue [74]. These findings suggested anti-lipogenic effects of ERβ. Furthermore, deletion of the ERβ gene protected female mice against diet-induced insulin resistance and glucose intolerance [73]. Together, both ER isoforms seem to participate in the anti-lipogenic actions of estrogens in adipose tissue.
Estrogens regulate glucose uptake in skeletal muscle

Approximately 75% of glucose clearance in response to insulin secretion is mediated by the skeletal muscle. The insulin signaling pathway that regulates glucose uptake includes insulin receptor, the insulin receptor substrate (IRS), phosphatidylinositol-3 (PI3K) and AKT kinase. Activation of this pathway eventually leads to translocation of the cytoplasmic glucose transporter 4 (GLUT4) to the cell membrane where it facilitates transport of glucose into the cell. GLUT4 is highly expressed in muscle and represents a rate-limiting step in the insulin-induced glucose uptake [75]. E2 modulates glucose homeostasis in the muscle mainly through its actions on key proteins of the insulin signaling pathway including the expression and translocation of GLUT4.

Skeletal muscle expresses both ERs, and in mice ERβ is the predominant isoform. Treatment of OVX rats with PPT increases GLUT4 expression and glucose uptake in skeletal muscle [76]. PPT treatment also increases GLUT4 translocation to the cell membrane of L6 myoblasts [77]. In contrast, DPN treatment decreases GLUT4 expression in the muscle in E2-deficient ArKO male mice [78]. In summary, ERα and ERβ display distinct actions on the expression of GLUT4.

Estrogens regulate metabolism in liver

Liver plays an important role in the maintenance of glucose homeostasis through glucose production by glycogenolysis and gluconeogenesis. Estrogens regulate liver glucose and lipid homeostasis and hepatic cholesterol output. Administration of E2 increased high density lipoprotein and triglycerides and decreased low density lipoprotein, total cholesterol, lipoprotein a, and fasting insulin in postmenopausal women [79]. Long term E2-treatment exhibited a major anti-diabetic effect in diabetic ob/ob mice, and decreased expression of lipogenic genes in the liver [63]. Recent studies have demonstrated that the use of antiestrogen therapy leads to abnormal lipid profile and steatosis [80].

ERα is the predominant ER isoform in hepatocytes [81]. ERαKO mice display hepatic insulin resistance, and the expression of genes involved in hepatic lipid synthesis was increased whilst expression of genes involved in lipid transport was decreased in these animals [82]. However, liver-selective ablation of ERα did not re-capitulate the metabolic phenotypes of ERαKO mice, indicating that hepatic ERα action may not be the responsible factor for the previously identified hepatic insulin resistance in ERαKO mice [83].

Estrogens regulate pancreatic β cell function

Estrogens are known regulators of pancreatic β cell function. It has rapid effects on β cells, regulating membrane depolarization, Ca2+ influx, insulin secretion, and overall glycemia. In addition, estrogens also protect β cells from apoptosis.

Both ERs have been identified in the nucleus and cell membrane of β cells. ERα is the predominant receptor isoform for regulation of the insulin level in the pancreas. The absence of ERα results in islet dysfunction and hyperinsulinemia [82]. In β cell islets isolated from Swiss albino mice, PPT treatment increased insulin content, while DPN treatment did not [84]. Moreover, protective effects of estrogens against apoptosis were also mainly mediated via ERα. E2-treatment inhibited streptozotocin (STZ)-induced β cell apoptosis, increased insulin production, and improved insulin resistance and glucose intolerance. The protective actions of E2 were abrogated in ERαKO female mice [85]. Furthermore, estrogens regulate the ATP-sensitive potassium (KATP) channels in β cells [86]. Closure of KATP channels is a pivotal event in the glucose-induced insulin release. Once the channel is closed, membrane depolarizes and insulin is released. The main function of ERβ in β cells seems to be a rapid regulation of KATP channel and insulin secretion, as it showed that E2 and DPN reduced the activity of KATP channels in β cells from wild type and ERαKO mice, but not in those from ERβKO mice [86].

Hormone replacement therapy in metabolic diseases

Pharmacological estrogens can reverse the progression of metabolic diseases. Estrogens have been approved by FDA for postmenopausal therapy. However, due to ubiquitous expression of ERs, the metabolic benefits provided by HRT are often associated with increased risk of heart disease, gynecological and breast cancer. One strategy to make estrogens therapeutically more efficient is to develop novel tissue selective SERMs. Another approach is to design novel molecules that would direct E2 to
target tissues without the undesirable effect of general E2 therapy. Recent reports on the development of a glucagon-like peptide-1 (GLP-1)-estrogen conjugate, which uses a peptide carrier to deliver estrogen selectively to specific tissues, showed high efficacy and much less side effects [87].

Summary

Estrogens play important roles in physiological processes via both ERα and ERβ. Abnormalities in estrogen signaling lead to different types of pathological conditions, such as cancer and metabolic diseases. In general, ERα expression increases at early stages of cancer, and acts as a tumor promoter. Antiestrogens are widely used for the treatment of breast cancer. On the contrary, ERβ levels are reduced during carcinogenesis and cancer progression, and act as a tumor suppressor. Accordingly, ERβ is a promising potential target for cancer therapy. However, some contradictory findings regarding the expression and functions of ERβ in cancer have been reported. Such discrepancies could reflect heterogeneity of patient populations. They may also be due to high heterogeneity of breast tissue, and low correlation between ERβ mRNA and protein levels. Thus, there is a clear need to further study the roles of ERβ in cancer.

Estrogens play important roles in maintenance of lipid and glucose homeostasis. They centrally regulate food intake and energy expenditure via action on the CNS, and they also act on peripheral tissues to maintain energy homeostasis. ERα and ERβ play distinct role in insulin and glucose metabolism. The major concern in using therapies targeting ER in treatment of metabolic disease is the risk of achieving undesirable effects. Further studies are needed to identify and develop new molecules that target ERs in selective metabolic tissues.

Practice points

- The presence of ERα is an important indicator for use of hormone therapy for breast cancer treatment.
- The use of antiestrogens such as tamoxifen, raloxifene, fulvestrant, anastrozole, letrozole or exemestane is recommended against ERα-positive breast cancer.

Research agenda

- The role of ERα and ERβ in cancer and metabolic disorders, and their potential for clinical applications need to be clarified.
- The mechanisms of resistance to antiestrogen treatment in breast cancer must be further investigated.
- New effective tissue and receptor selective antiestrogens should be identified.

Acknowledgments

Jan-Åke Gustafsson receives support from The Swedish Cancer Fund and the Robert A. Welch Foundation (E-0004).

References


